

Increasing Cancer Screening: Provider Incentives

Summary Evidence Table

Completed Screening

Study	Location Intervention Comparison	Study population description Sample size	Effect measure	Reported baseline	Reported effect	Follow- up time
<p>Author (year): Rosenthal (2005)*</p> <p>Study Period: 2001–2004</p> <p>Design Suitability: Greatest</p> <p>Study Design: Group non-randomized trial</p> <p>Quality of Execution: Good</p> <p>Outcome Measurement: Completed breast and cervical cancer screening (Health plan performance reports based on administrative data)</p>	<p>Location: US, California, Oregon and Washington</p> <p>Intervention: Quarterly practice bonus of ~ \$0.23 per member per month for each performance target met. Bonus potential represents ~5% of capitation (\$27 per enrollee).</p> <p>Comparison: Physician groups in the Pacific Northwest (Oregon and Washington).</p>	<p>Study population: Physician groups from a large health plan, which had a minimum 1000 Pacific Care Commercial and 100 Secure Horizons (Medicare Advantage) members.</p> <p>Sample Size: Intervention: n=134 Comparison: n=33 (PAP) n=32 (MAM)</p>	<p>Absolute change in completed breast and cervical cancer screening.</p>	<p>PAP: Intervention: 39.2%</p> <p>Comparison: 55.4%</p> <p>Mammography (MAM):</p> <p>Intervention: 66.1%</p> <p>Comparison: 72.4%</p>	<p>PAP: +3.6 pct pts (p<.05)</p> <p>MAM: +1.7 pct pts(p>.05)</p>	<p>1 yr</p>

Study	Location Intervention Comparison	Study population description Sample size	Effect measure	Reported baseline	Reported effect	Follow- up time
<p>Author (year): Armour (2004)*</p> <p>Study Period: 2000-2001</p> <p>Design Suitability: Least</p> <p>Study Design: Before/After</p> <p>Quality of Execution: Fair</p> <p>Outcome Measurement: Completed CRC screening (based on managed care health plan claims data)</p>	<p>Location: US, Southeast – patients residing in one state</p> <p>Intervention: Year end bonuses for physicians.</p> <p>Comparison: Pre-intervention period.</p>	<p>Study population: Individual practice association physicians who were eligible for year end bonuses according to proprietary criteria and their commercially insured patients age=50 who were continuously enrolled in the health plan in 2000 and 2001.</p> <p>Sample Size: Intervention: n=3691 patients</p> <p>Comparison: n=3058 patients</p>	<p>Absolute change in colorectal cancer screening.</p>	<p>Fecal Occult Blood Test (FOBT): 17.8%</p> <p>Flexible sigmoidoscopy or colonoscopy (FS/C): 8.6%</p> <p>Double Contrast Barium Enema (DCBE): 1.3%</p>	<p>FOBT: +2.8 pct pts (p<.05)</p> <p>FS/C: +1.2 pct pts (p>.05)</p> <p>DCBE: -0.1 pct pts (p>.05)</p>	<p>1 yr</p>
<p>Author (year): Grady (1997)</p> <p>Study Period: not reported</p> <p>Design Suitability: Greatest</p> <p>Study Design: Group randomized trial</p> <p>Quality of Execution: Fair</p> <p>Outcome Measurement: Mammography completion rates (Chart audit)</p>	<p>Location: US, Dayton, OH & Springfield, MA</p> <p>Intervention 1: Provider reminder</p> <p>Intervention 2: Provider reminder, provider assessment and feedback, provider incentive (Physician bonus based on the percentage referred during each audit period, i.e., \$50 for a 50% referral rate)</p>	<p>Study population: Community-based general practice, family practice or internal medicine practices, with 1-6 physicians and which provide primary care for at least 50 women age 50 or older per month per physician.</p> <p>Sample Size: Intervention 1: n=18 Intervention 2: n=20</p>	<p>Absolute change in mammography completion rates</p>	<p>Intervention 1: 17.7%</p> <p>Intervention 2: 12.6%</p>	<p>I₂ vs. I₁ = -2.0 pct pts (p>.05)</p>	<p>1 yr</p>

Study	Location Intervention Comparison	Study population description Sample size	Effect measure	Reported baseline	Reported effect	Follow- up time
<p>Author (year): Reid (1991)</p> <p>Study Period: 1990</p> <p>Design Suitability: Least</p> <p>Study Design: Before/After</p> <p>Quality of Execution: Fair</p> <p>Outcome Measurement: Proportion of women with cervical cancer screening (Lab record audit)</p>	<p>Location: Perth and Kinross, Scotland</p> <p>Intervention: A new contract for general practitioners revamped the remuneration system for cervical smear testing. The new contract set targets of 50% and 80% linked directly to remuneration.</p> <p>Comparison: Pre-intervention period under prior remuneration system (item of service basis).</p>	<p>Study population: Women ages 21 – 60 without a hysterectomy who attend one of the eligible 26 practices in the area.</p> <p>Sample Size: N not reported</p>	<p>Absolute change in proportion of women with cervical cancer screening.</p>	<p>78%</p>	<p>8 pct pts (p<.05)</p>	<p>6 mos</p>

*From the updated search period.

Offered Screening

Study	Location Intervention Comparison	Study population description Sample size	Effect measure	Reported baseline	Reported effect	Follow- up time
<p>Author (year): Hillman (1998)</p> <p>Study Period: 1993 – 1995</p> <p>Design Suitability: Greatest</p> <p>Study Design: Group randomized trial</p> <p>Quality of Execution: Fair</p> <p>Outcome Measurement: Compliance with screening (physician referral for screening with or without actual test results). (Chart audit)</p>	<p>Location: US, Philadelphia, PA</p> <p>Intervention: A financial practice incentive based on aggregate compliance with cancer screening. Semi-annual feedback was given to the providers, documenting site performance for each guideline, an aggregate score across all measures, and plan-wide scores.</p> <p>Comparison: Usual payment</p>	<p>Study population: the 52 largest primary care sites in the area</p> <p>Sample size: Intervention: n=26 Comparison: n=26</p>	<p>Absolute change in referral/ screening rates</p>	<p><u>Pap</u> Baseline Intervention=25.4% Control=16.5%</p> <p><u>Mammogram</u> Baseline Intervention=40.9% Control = 34.4%</p> <p><u>Colorectal</u> Baseline Intervention=14.9% Control = 10.8%</p>	<p>PAP: -0.8 pct pts (p>.05)</p> <p>Mammography: -1.5 pct pts (p>.05)</p> <p>Colorectal: 2.2 pct pts (p>.05)</p>	<p>18 mos</p>

Study	Location Intervention Comparison	Study population description Sample size	Effect measure	Reported baseline	Reported effect	Follow- up time
<p>Author (year): Grady (1997)</p> <p>Study Period: Not reported</p> <p>Design Suitability: Greatest</p> <p>Study Design: Group randomized trial</p> <p>Quality of Execution: Fair</p> <p>Outcome Measurement: Offered mammography rates (Chart audit)</p>	<p>Location: US, Greater Dayton, OH and Greater Springfield, MA</p> <p>Intervention 1: Provider reminder</p> <p>Intervention 2: Provider reminder, provider assessment and feedback, provider incentive (Physician bonus based on the percentage referred during each audit period, i.e., \$50 for a 50% referral rate)</p>	<p>Study population: Community-based general practice, family practice or internal medicine practices, with 1-6 physicians and which provide primary care for at least 50 women age 50 or older per month per physician.</p> <p>Sample Size: Intervention 1: n=18 Intervention 2: n=20</p>	<p>Absolute change in mammography referral rates</p>	<p>Intervention 1: 25.8%</p> <p>Intervention 2: 19.0%</p>	<p>I_2 vs. $I_1 = 1.0$ pct pts ($p > .05$)</p>	<p>1 yr</p>